# Dapagliflozin Post Marketing Surveillance in HF and CKD

> **NCT05134701** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 815 (actual)

## Conditions studied

- Heart Failure
- Chronic Kidney Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05134701
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-10
- **Primary completion:** 2024-05-20
- **Final completion:** 2024-05-20
- **Target enrollment:** 815 (ACTUAL)
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05134701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05134701, "Dapagliflozin Post Marketing Surveillance in HF and CKD". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05134701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*